Oncology Research and Treatment

Published by: S. Karger AG  

People

  1. Matasar
    Matasar
  2. Zelenetz
    Zelenetz
  3. Horwitz
    Horwitz
  4. Palomba
    Palomba
  5. Salles
    Salles
  6. Younes
    Younes

Groups

  1. Center for Hematologic Malignancies (19)
  2. Department of Medicine (19)
  3. Hematologic Malignancies, Division of (19)
  4. Lymphoma (19)
  5. Survivorship Research (8)
  6. Population Sciences Research Program (3)
  7. Executive Committee, Center for Hematologic Malignancies (1)
Search Within
  1. "Lymphoma"
Formats
  1. Meeting Abstract (19)
Groups
  1. Center for Hematologic Malignancies (19)
  2. Department of Medicine (19)
  3. Hematologic Malignancies, Division of (19)
  4. Lymphoma (19)
  5. Survivorship Research (8)
  6. Population Sciences Research Program (3)

More Groups

People
  1. Matthew Matasar (8)
  2. Andrew Zelenetz (4)
  3. Maria Palomba (3)
  4. Steven Horwitz (3)
  5. Gilles Salles (2)
  6. Anas Younes (1)
Years
  1. 2023 (2)
  2. 2022 (3)
  3. 2021 (3)
  4. 2020 (2)
  5. 2019 (3)
  6. 2018 (1)

More Years

Publishers
  1. S. Karger AG (19)

Results (19)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Mosunetuzumab monotherapy demonstrates durable efficacy with a manageable safety profile in patients with relapsed/refractory follicular lymphoma who received ≥2 prior therapies: Updated results from a pivotal phase II study
    Meeting Abstract

    Dietrich, S.; Bartlett, N. L.; Sehn, L. H.; Matasar, M.; Schuster, S. J.; Assouline, S.; Giri, P.; Kuruvilla, J.; Canales, M.; Fay, K.; more...
    Oncology Research and Treatment (2023)

    Fulltext@MSK | Save
  • Subcutaneous mosunetuzumab is active with a manageable safety profile in patients (pts) with relapsed/refractory (R/R) B-cell non-Hodgkin lymphomas (B-NHL): Updated results from a phase I/II study
    Meeting Abstract

    von Tresckow, B.; Budde, L. E.; Bartlett, N. L.; Giri, P.; Schuster, S. J.; Assouline, S.; Yoon, S. S.; Fay, K.; Matasar, M.; Gutierrez, N. C.; more...
    Oncology Research and Treatment (2023)

    Fulltext@MSK | Save
  • Polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP ) versus rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) therapy in patients with previously untreated diffuse large B-cell lymphoma (DLBCL): Results from the phase III POLARIX study
    Meeting Abstract

    Dietrich, S.; Tilly, H.; Morschhauser, F.; Sehn, L. H.; Friedberg, J. W.; Trněný, M.; Sharman, J.; Herbaux, C.; Burke, J. M.; Matasar, M.; more...
    Oncology Research and Treatment (2022)

    Fulltext@MSK | Save
  • Polatuzumab vedotin + rituximab, cyclophosphamid, doxorubicin und prednison (Pola-R-CHP) im vergleich zu rituximab, cyclophosphamid, doxorubicin, vincristin und prednison (R-CHOP) bei patient: Innen mit unbehandeltem diffusemgroßzelligem B-zell-lymphom (DLBCL): Ergebnisse der phase III POLARIX studie
    Meeting Abstract

    Dietrich, S.; Tilly, H.; Morschhauser, F.; Sehn, L. H.; Friedberg, J.; Trněný, M.; Sharman, J. P.; Herbaux, C.; Burke, J. M.; Matasar, M.; more...
    Oncology Research and Treatment (2022)

    Fulltext@MSK | Save
  • Mosunetuzumab-monotherapie ist eine wirksame und gut verträgliche behandlungsoption bei patienten mit rezidiviertem/refraktärem follikulärem lymphom, die zuvor bereits ≥2 therapielinien erhalten haben: Wichtige ergebnisse einer phase-I/II-studie
    Meeting Abstract

    Hess, G.; Budde, L. E.; Sehn, L. H.; Matasar, M.; Schuster, S. J.; Assouline, S.; Giri, P.; Kuruvilla, J.; Canales, M.; Dietrich, S.; more...
    Oncology Research and Treatment (2022)

    Fulltext@MSK | Save
  • Polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory diffuse large B-cell lymphoma: Updated results of a phase Ib/II randomized study and preliminary results of a Single-arm extension
    Meeting Abstract

    Sehn, L. H.; Hess, G.; Hertzberg, M.; Opat, S.; Herrera, A. F.; Assouline, S.; Flowers, C. R.; Kim, T. M.; McMillan, A.; Ozcan, M.; more...
    Oncology Research and Treatment (2021)

    Fulltext@MSK | Save
  • ECHELON-2, (NCT01777152), 5-year results of a randomised, double-blind, phase 3 study of frontline brentuximab vedotin plus CHP vs CHOP in patients with CD30-positive peripheral T-cell lyphoma
    Meeting Abstract

    Trümper, L.; O'Connor, O. A.; Pro, B.; Illidge, T.; Advani, R.; Bartlett, N. L.; Christensen, J. H.; Morschhauser, F.; Domingo-Domenech, E.; Rossi, G.; more...
    Oncology Research and Treatment (2021)

    Fulltext@MSK | Save
  • CHRONOS-3: Randomized Phase III study of copanlisib plus rituximab vs rituximab/placebo in relapsed indolent non-Hodgkin lymphoma (iNHL)
    Meeting Abstract

    Dreyling, M.; Matasar, M. J.; Capra, M.; Özcan, M.; Lv, F.; Li, W.; Yanez, E.; Sapunarova, K.; Lin, T.; Jin, J.; more...
    Oncology Research and Treatment (2021)

    Fulltext@MSK | Save
  • Exploratory analysis of retreatment with brentuximab vedotin (BV) after frontline treatment with brentuximab vedotin and CHP (A+CHP) for patients (pts) with CD30+ peripheral T-cell lymphoma (ECHELON-2)
    Meeting Abstract

    Trümper, L.; Pro, B.; Horwitz, S.; O'connor, O.; Tilly, H.; Choi, I.; Gritti, G.; Fox, C.; Alpdogan, O.; Mayer, J.; more...
    Oncology Research and Treatment (2020)

    Fulltext@MSK | Save
  • Safety and efficacy results from Transcend NHL 001, a multicenter phase 1 study of lisocabtagene maraleucel (liso-cel) In relapsed/refractory (R/R) large B-cell lymphoma (LBCL)
    Meeting Abstract

    Abramson, J.; Palomba, M. L.; Gordon, L.; Lunning, M.; Wang, M.; Arnason, J.; Mehta, A.; Purev, E.; Maloney, D.; Andreadis, C.; more...
    Oncology Research and Treatment (2020)

    Fulltext@MSK | Save

    • Oncology Research and Treatment – authorized name for:

    Name ISSN / ISBN Publisher
    Oncology Research and Treatment 2296-5270 Karger
    Oncology research and treatment 22965262 Unknown
    Oncology Research and Treatment 2296-5270 S. Karger AG
    Oncology Research and Treatment 2296-5270 S. Karger AG